 CRANBURY, N.J., May 14, 2021 PRNewswire -- Palatin Technologies, Inc. NYSE American: PTN, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that it will host a key opinion leader KOL webinar on melanocortin agonists for treating ocular indications, with a primary focus on PL9643, the Companys lead asset. 